Taysha Gene Therapies Announces Proposed Public Offering of Common Stock
October 25 2022 - 4:01PM
Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric,
pivotal-stage gene therapy company focused on developing and
commercializing AAV-based gene therapies for the treatment of
monogenic diseases of the central nervous system (CNS) in both rare
and large patient populations, today announced that it intends to
offer and sell, subject to market conditions, $30 million of shares
of its common stock in an underwritten public offering. All shares
of common stock to be sold in the offering will be offered by
Taysha. Taysha also intends to grant the underwriter a 30-day
option to purchase up to an additional 15% of the shares of its
common stock offered in the public offering under the same terms
and conditions. The offering is subject to market conditions, and
there can be no assurance as to whether or when the offering may be
completed, or the actual size or terms of the offering.
Goldman Sachs & Co. LLC is acting as sole book-runner for
the offering.
A shelf registration statement relating to the shares of common
stock offered in the public offering described above was filed with
the Securities and Exchange Commission (the “SEC”) on October 5,
2021 and declared effective by the SEC on October 14, 2021. The
offering will be made only by means of a written prospectus and
prospectus supplement that form a part of the registration
statement. A preliminary prospectus supplement and accompanying
prospectus relating to the offering will be filed with the SEC and
will be available on the SEC’s website at www.sec.gov. Copies of
the preliminary prospectus supplement and the accompanying
prospectus, when available, may also be obtained by contacting
Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200
West Street, New York, NY 10282, or by telephone at (866) 471-2526,
or by email at prospectus-ny@ny.email.gs.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy the securities being offered, nor
shall there be any sale of the securities being offered in any
state or other jurisdiction in which such offer, solicitation or
sale would be unlawful prior to the registration or qualification
under the securities laws of any such state or other
jurisdiction.
About Taysha Gene
Therapies
Taysha Gene Therapies (Nasdaq: TSHA) is on a mission to
eradicate monogenic CNS disease. With a singular focus on
developing curative medicines, we aim to rapidly translate our
treatments from bench to bedside. We have combined our team’s
proven experience in gene therapy drug development and
commercialization with the world-class UT Southwestern Gene Therapy
Program to build an extensive, AAV gene therapy pipeline focused on
both rare and large-market indications. Together, we leverage our
fully integrated platform—an engine for potential new cures—with a
goal of dramatically improving patients’ lives.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Words such as “anticipates,” “believes,” “expects,”
“intends,” “projects,” “plans,” and “future” or similar expressions
are intended to identify forward-looking statements.
Forward-looking statements include statements concerning the
potential of Taysha’s product candidates, including its preclinical
product candidates, to positively impact quality of life and alter
the course of disease in the patients Taysha seeks to treat, its
research, development and regulatory plans for its product
candidates, and Taysha’s anticipated public offering, including the
uncertainties related to market conditions and the completion of
the public offering on the anticipated terms, if at all.
Forward-looking statements are based on management’s current
expectations and are subject to various risks and uncertainties
that could cause actual results to differ materially and adversely
from those expressed or implied by such forward-looking statements.
Accordingly, these forward-looking statements do not constitute
guarantees of future performance, and you are cautioned not to
place undue reliance on these forward-looking statements. Risks
regarding Taysha’s business are described in detail in its SEC
filings, including in Taysha’s Annual Report on Form 10-K for the
full-year ended December 31, 2021, and Taysha’s Quarterly Report on
Form 10-Q for the quarter ended June 30, 2022, both of which are
available on the SEC’s website at www.sec.gov. Additional
information will be made available in other filings that Taysha
makes from time to time with the SEC. Such risks may be amplified
by the impacts of the COVID-19 pandemic. These forward-looking
statements speak only as of the date hereof, and Taysha disclaims
any obligation to update these statements except as may be required
by law.
Company Contact:Kimberly Lee, D.O. Chief
Corporate Affairs OfficerTaysha Gene
Therapiesklee@tayshagtx.com
Media Contact:Carolyn HawleyCanale
Evokecarolyn.hawley@evokegroup.com
Taysha Gene Therapies (NASDAQ:TSHA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Taysha Gene Therapies (NASDAQ:TSHA)
Historical Stock Chart
From Jul 2023 to Jul 2024